Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase II, single arm trial (GIM11-BERGI).
ESMO Open
; 6(2): 100054, 2021 04.
Article
in En
| MEDLINE
| ID: mdl-33601296
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Breast Neoplasms
Type of study:
Clinical_trials
Limits:
Female
/
Humans
Language:
En
Journal:
ESMO Open
Year:
2021
Type:
Article
Affiliation country:
Italy